1 / 6GLP Peptides · Metabolic Peptides
Multi Dose | Finished in the USA
Survodutide · 12mg
$144.00$240.00
For Research Use Only. Not for human consumption or therapeutic treatment.
Multi Dose | Finished in the USA
Survodutide is a dual-agonist peptide with binding activity at both GLP-1 and glucagon receptors. It appears in published literature examining incretin signaling, hepatic lipid metabolism, and energy-expenditure pathways.
Supplied as a lyophilized research reagent. HPLC-verified to ≥99% purity.
For Research Use Only. Not for human or veterinary use.
Survodutide is a dual-agonist peptide that binds both GLP-1 (glucagon-like peptide-1) and glucagon receptors, placing it in the incretin class of research compounds. It was originally developed by Boehringer Ingelheim as an investigational compound.
Its two-receptor mechanism is of research interest because it engages incretin signaling and glucagon signaling simultaneously, a profile that differs from single-target GLP-1 analogues. Published preclinical and early clinical literature has examined its activity across metabolic, hepatic, and energy-expenditure pathways.
Real Peptides supplies Survodutide as a laboratory research reagent. It is not a drug, is not approved for any therapeutic use, and is not for human or veterinary administration.
Survodutide appears in published research examining incretin biology, hepatic lipid metabolism, and receptor pharmacology. Points of research interest include:
For Research Use Only. Not for human or veterinary use.
Survodutide differs from single-target incretin compounds through its glucagon receptor activity, which introduces a second signaling pathway. In published comparative literature, points of distinction studied include:
Real Peptides supplies Survodutide with third-party HPLC verification and per-lot COAs.
Survodutide is a dual-agonist peptide with binding activity at GLP-1 and glucagon receptors. Real Peptides supplies it as a laboratory research reagent.
Published literature examines Survodutide in the context of incretin receptor signaling, hepatic lipid metabolism, and energy-expenditure pathways in preclinical models.
No. Survodutide is an investigational compound and is not approved by the FDA for any use. Real Peptides supplies it strictly as a research reagent, not for human or veterinary use.
Survodutide binds both GLP-1 and glucagon receptors. Published research examines the downstream signaling of each pathway in model systems.
Store lyophilized material at -20°C, protected from light. Once reconstituted, refrigerate at 2–8°C.
